Liquid biopsies for cancer: From bench to clinic

Zhenhui Chen, Chenghao Li, Yue Zhou, Yinghao Yao, Jiaqi Liu, Min Wu, Jianzhong SuMedComm 2023 · DOI

TL;DR

This review provides a comprehensive overview of liquid biopsies for cancer, highlighting their evolution from early detection to clinical application. It emphasizes the growing importance of epigenetic markers, alongside genetic ones, for a more robust and personalized approach to cancer management.

What Problem Does This Paper Address?

Traditional tissue biopsies, while the gold standard for cancer diagnosis, have significant limitations. They are invasive, can be difficult to obtain repeatedly, and may not fully capture the heterogeneity of a tumor, especially in late-stage disease. This creates an urgent need for less invasive, more accessible, and comprehensive methods for cancer detection, monitoring, and treatment guidance. Liquid biopsies, which analyze tumor-derived material in bodily fluids like blood, offer a promising solution to these challenges. However, the field is complex, with diverse circulating entities and detection technologies, making it difficult for researchers and clinicians to navigate. This paper aims to systematically review and synthesize the current state of liquid biopsy research, focusing on both genetic and epigenetic markers, to provide a clearer understanding and guide future clinical applications.

Methods

The paper systematically reviews existing literature on various circulating components used in liquid biopsies. It categorizes these components into two main groups: those based on genetic alterations (beyond epigenetics) and those based on epigenetic alterations.

  • Genetic Alterations: This includes the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) for mutations, copy number variations, and fragmentomics.
  • Epigenetic Alterations: This focuses on DNA methylation, DNA 5-hydroxymethylation (5hmC), histone post-translational modifications (PTMs) on circulating nucleosomes, and circulating non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) and long non-coding RNAs (lncRNAs).

The review discusses the biological features and clinical applications of each component, highlighting advances in experimental techniques (e.g., high-throughput sequencing, ChIP-seq, bisulfite sequencing) and computational approaches (e.g., machine learning, deep learning) used for their detection and analysis.

Datasets

Not explicitly detailed as a single dataset. The paper synthesizes findings from numerous published studies and clinical trials, referencing data from various sources including:

  • PubMed publications
  • National Cancer Institute website (clinicaltrials.gov)
  • Specific clinical trials (e.g., SWOG-S0500, METABREAST STIC CTC, DETECT-A)
  • Commercial product data (e.g., Cobas EGFR mutation Test v2, Guardant 360 CDx, CancerSEEK, Galleri)

Key Insights and Ideas

  • Epigenetics as a Highlight: The paper strongly emphasizes the unique advantages of epigenetic markers (DNA methylation, histone modifications, ncRNAs) in liquid biopsies. Their tissue-specific nature, reversibility, and ability to precede genetic alterations make them powerful tools for early detection and distinguishing tumor origin.
  • Complementarity is Key: No single biomarker is likely to be sufficient for accurate cancer diagnosis or management. The future lies in integrating multiple types of biomarkers (genetic, epigenetic, protein) to achieve more reliable and comprehensive results.
  • CTCs as Metastasis Drivers: Circulating tumor cells (CTCs) are not just passive indicators but actively contribute to metastasis, especially when clustered. Targeting these clusters offers a potential therapeutic avenue.
  • ctDNA's Maturation: While ctDNA analysis for mutations is well-established and has led to FDA-approved tests, the field is rapidly expanding to include epigenetic alterations within ctDNA for more nuanced insights.
  • Nucleosomes as Stable Biomarkers: Circulating nucleosomes, carrying histone PTMs, are relatively stable in biological fluids, making them promising candidates for early detection and monitoring, especially when analyzed in panels.
  • ncRNAs' Protective Nature: Circulating ncRNAs, particularly miRNAs, are protected from degradation by extracellular vesicles, making them robust and detectable biomarkers.

Key Results

The paper doesn't present new experimental results but rather synthesizes findings from existing research. Key outcomes highlighted include:

  • FDA-Approved Tests: Several liquid biopsy tests have received FDA approval, including companion diagnostics for specific mutations (e.g., Cobas EGFR mutation Test v2, FoundationOne Liquid CDx) and early detection assays (e.g., Epi proColon for CRC, CancerSEEK).
  • Clinical Utility Demonstrated: Liquid biopsy markers have shown promise in:
  • Early Diagnosis: Detecting cancer years before radiological signs (e.g., lung cancer from chronic obstructive pulmonary disease patients).
  • Prognosis and Recurrence Monitoring: Providing valuable information for treatment decisions and tracking disease progression.
  • Therapeutic Response Monitoring: Guiding treatment adjustments based on changes in biomarker levels.
  • High Sensitivity and Specificity: While individual markers may have limitations, panels of epigenetic markers have demonstrated high sensitivity and specificity in distinguishing cancer patients from healthy controls, sometimes exceeding traditional markers. For example, a panel of four epigenetic circulating nucleosome biomarkers combined with CA 19-9 showed 92% sensitivity and 90% specificity for PC detection.
  • Machine Learning's Role: Advanced computational approaches, particularly machine learning, are crucial for integrating multi-parameter data from liquid biopsies to achieve accurate cancer detection and classification.

Limitations and Future Work

  • Limitations:
    • Low Concordance: Inconsistencies between studies due to variations in experimental and analytical methodologies.
  • Low Quantity: The small amount of circulating biomarkers in biological fluids poses a challenge for detection.
  • Distinguishing Tumor vs. Normal: Differentiating tumor-derived signals from background noise from normal cellular processes remains difficult.
  • Lack of Standardized Methodology: The absence of standardized protocols for sampling, isolation, detection, and analysis hinders comparability across studies.
  • Need for Clinical Evaluation Systems: A lack of established guidelines for evaluating the clinical utility of liquid biopsy results, similar to RECIST for imaging.
  • Future Work:
    • Combination of Biomarkers: Developing panels that integrate genetic and epigenetic markers for enhanced accuracy and reliability.
  • Standardization: Establishing standardized protocols and quality control measures.
  • Development of Reference Materials: Creating reference materials for better quality control and quantification.
  • Interventional Studies: Conducting more rigorous, well-designed interventional studies to demonstrate clinical utility.
  • Exploration of Other Bodily Fluids: Expanding research beyond blood to include urine, cerebrospinal fluid, and pleural effusions.
  • Advanced Computational Tools: Further development of machine learning and big data approaches for more efficient and accurate analysis of complex liquid biopsy data.

Summary updated

Abstract

Over the past two decades, liquid biopsy has been increasingly used as a supplement, or even, a replacement to the traditional biopsy in clinical oncological practice, due to its noninvasive and early detectable properties. The detections can be based on a variety of features extracted from tumor‑derived entities, such as quantitative alterations, genetic changes, and epigenetic aberrations, and so on. So far, the clinical applications of cancer liquid biopsy mainly aimed at two aspects, prediction (early diagnosis, prognosis and recurrent evaluation, therapeutic response monitoring, etc.) and intervention. In spite of the rapid development and great contributions achieved, cancer liquid biopsy is still a field under investigation and deserves more clinical practice. To better open up future work, here we systematically reviewed and compared the latest progress of the most widely recognized circulating components, including circulating tumor cells, cell-free circulating DNA, noncoding RNA, and nucleosomes, from their discovery histories to clinical values. According to the features applied, we particularly divided the contents into two parts, beyond epigenetics and epigenetic-based. The latter was considered as the highlight along with a brief overview of the advances in both experimental and bioinformatic approaches, due to its unique advantages and relatively lack of documentation.
BibTeX
@inproceedings{chen2023liquid,
  author = {Zhenhui Chen and Chenghao Li and Yue Zhou and Yinghao Yao and Jiaqi Liu and Min Wu and Jianzhong Su},
  title = {{Liquid biopsies for cancer: From bench to clinic}},
  booktitle = {MedComm},
  year = {2023},
  doi = {10.1002/mco2.329},
}
Figure